Product
Tritace Plus
Aliases
The reference product, Tritace® Plus tablet 10 mg/25 mg
1 clinical trial
1 indication
Indication
bioequivalenceClinical trial
Open-label With Blinding Bioanalytical Stage Randomized Crossover Two Period Two Sequences Single Dose Bioequivalence Study of Two Formulations Ramipril/Hydrochlorothiazide Tablets 10 mg/25 mg (Manufacturer: Pharmtechnology LLC, Republic of Belarus) and Tritace® Plus Tablets 10 mg/25 mg (Manufacturer: Sanofi S.p.A., Italy; Holder of the Registration Certificate: Sanofi-Aventis Deutschland GmbH, Germany) in Healthy Volunteers Under Fasting ConditionsStatus: Completed, Estimated PCD: 2023-02-22